Search Results
Apr 28, 2026, 09:47 ET Pew Report Charts Path to Accelerate Use of Distributed Energy Nationwide
have barriers to their broad adoption. Now is the time to pull those barriers down and bring more energy choices directly to customers," said Pat Wood III, a former Federal Energy Regulatory Commission chairman under President George W. Bush (R) and a Pew DER Advisory Council co-chair. "DERs are a proven,
More news about: The Pew Charitable Trusts
Apr 28, 2026, 09:40 ET Bitmine Immersion Technologies (BMNR) annonce que ses avoirs en ETH atteignent le record mondial sans précédent de 5,078 millions de tokens, et que ses avoirs en cryptomonnaie et en liquidités totalisent 13,3 milliards de dollars
continue de recevoir le soutien d'un groupe d'investisseurs institutionnels de premier plan, dont Cathie Wood d'ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital et l'investisseur privé Thomas « Tom » Lee, pour atteindre l'objectif de Bitmine visant à acquérir 5 % du nombre
More news about: Bitmine Immersion Technologies, Inc.
Apr 28, 2026, 09:30 ET Former Chief Justices and Federal Judges Unite at Unprecedented Speak Up for Justice Forum to Sound Alarm on Threats to Courts
Gorre Cantil-Sakauye – Former Chief Justice of CaliforniaMaureen O'Connor – Former Chief Justice of OhioJohn E. Jones III – Retired U.S. District Court for the Middle District of PennsylvaniaBernice Bouie Donald – Former U.S. Court of Appeals for the Sixth
More news about: Kiesel Law
Apr 28, 2026, 09:28 ET Bitmine Immersion Technologies (BMNR) kondigt aan dat de ETH-bezittingen een nooit gezien wereldrecord bereiken van 5,078 miljoen tokens, met totale crypto- en contante bezittingen van 13,3 miljard dollar
Bitmine wordt ondersteund door een vooraanstaande groep institutionele investeerders, waaronder Cathie Wood van ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital en persoonlijke investeerder Thomas 'Tom' Lee ter ondersteuning van Bitmines doel om 5% van alle ETH te verwerven.
More news about: Bitmine Immersion Technologies, Inc.
Apr 28, 2026, 09:11 ET C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
100+ projects spanning diagnostic and therapeutic programs, including 5 programs at IND or IND-enabling stage, 7 in clinical supply, and 2 in Phase III clinical trials. For more information, visit www.c-raytherapeutics.com
More news about: C Ray Therapeutics
Apr 28, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR
applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (iii) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (iv) as a result, defendants' public statements were materially
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET The Gross Law Firm Reminds Pinterest, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 29, 2026 - PINS
impact of U.S. tariffs on the macroeconomic environment in which the Company operated, including the foreseeable impact on its advertising partners; (iii) the impact of the foregoing on Pinterest's advertising revenues was significant enough that Pinterest was facing and/or likely to face an imminent restructuring;
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET Lost Money on Upstart, Inc. (UPST)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
performing its risk-separation processes; (ii) accordingly, Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (iii) Model 22's overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart's revenue results,
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET Lost Money on ODDITY Tech Ltd. (ODD)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (iii) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET CWH DEADLINE: The Gross Law Firm Reminds Camping World Holdings, Inc. Investors of Upcoming Securities Class Action Deadline
optimize profit using "data analytics;" (ii) the Company overstated the retail demand of consumers it was experiencing and/or reasonably expected; (iii) as a result, the Company would require "strict, corrective inventory management objectives," negatively impacting gross profit and margins; (iv) the
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET BW Deadline Alert: The Gross Law Firm Reminds Babcock & Wilcox Enterprises, Inc. (BW) Investors of Securities Class Action Deadline on June 15, 2026
(ii) Applied Digital did not need the products and services that B&W would purportedly supply pursuant to the power generation LNTP and contract; (iii) the foregoing, at the very least, would raise questions about the parties' actual intent behind entering into the power generation LNTP and contract,
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET GEMI Shareholder Alert: Gemini Space Station, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
platform; (ii) Gemini had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, Gemini's post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that Gemini
More news about: The Gross Law Firm
Apr 28, 2026, 09:00 ET Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol. 2017;69(11):1427–50.iii Cook S, Walker A, Hügli O, Togni M, Meier B. Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based
More news about: Abbott
Apr 28, 2026, 08:38 ET World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical
delivers a toxin with high purity and high specific activity.In a pivotal randomized, double-blind, placebo- and active-controlled multicenter Phase III clinical trial conducted in China, Retoxin® met all primary and secondary endpoints. The study demonstrated superior efficacy, favorable safety
More news about: Claruvis Pharmaceutical
Apr 28, 2026, 08:38 ET World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical
delivers a toxin with high purity and high specific activity.In a pivotal randomized, double-blind, placebo- and active-controlled multicenter Phase III clinical trial conducted in China, Retoxin® met all primary and secondary endpoints. The study demonstrated superior efficacy, favorable safety
More news about: Claruvis Pharmaceutical
Apr 28, 2026, 08:35 ET Letter from Barry Diller to IAC Shareholders: IAC Announces Name Change to People Incorporated
policies, economics or features (including those implemented by Google), as well as the potential expiration or modification of key commercial agreements, (iii) our ability to effectively market our products and services in a cost-efficient manner across evolving digital channels, (iv) our dependence on advertising
More news about: IAC
Apr 28, 2026, 08:30 ET HUHUTECH International Group Inc. Announces Fiscal Year 2025 Financial Results
contributed by (i) an approximately $18.6 million increase in share-based compensation, (ii) an approximately $1.3 million increase in impairment losses, (iii) a decrease of consulting and audit fees approximately $1.6 million.Research and development expenses were $0.9
More news about: HUHUTECH International Group Inc.
Apr 28, 2026, 07:27 ET Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
non-immunosuppressive oral, more accessible therapy earlier in the treatment pathway."MAVERIC Phase III TrialMAVERIC is a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent
More news about: Cardiol Therapeutics Inc.
Apr 28, 2026, 07:10 ET Amber International Holding Limited Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
from continuing operations represents net income/(loss) from continuing operations before (i) depreciation and amortization, (ii) finance income, net, (iii) income tax credit, (iv) share-based compensation, (v) other gains, net, (vi) unrealized loss in fair value of digital assets, and (vii) cost related
More news about: Amber International Holding Limited
Apr 28, 2026, 07:02 ET Zentiva odwołuje się od decyzji TSUE w sprawie Dyrektywy dotyczącej oczyszczania ścieków komunalnych
i inne przedsiębiorstwa w marcu 2025. W ramach skargi o stwierdzenie nieważności, Zentiva kwestionuje przepisy art. 9 i 10 w związku z Załącznikiem III do Dyrektywy UWWTD, która ustanawia rozszerzoną odpowiedzialność producenta (ROP) polegającą na obowiązku pokrycia co najmniej 80% kosztów tzw. oczyszczania
More news about: Zentiva Group a.s.
Apr 28, 2026, 07:02 ET Shutterstock Reports First Quarter 2026 Financial Results
performance and overall liquidity; (ii) facilitate management's internal comparisons of the historical operating performance of its business operations; (iii) facilitate management's external comparisons of the results of its overall business to the historical operating performance of other companies that
More news about: Shutterstock, Inc.
Apr 28, 2026, 07:00 ET BANKFIRST CAPITAL CORPORATION Reports First Quarter 2026 Earnings of $8.39 Million
"Basel III Rules," apply to both depository institutions and (subject to certain exceptions not applicable to the Company) their holding companies. The Basel III Rules also establish a "capital conservation buffer" of 2.5% above the regulatory minimum risk-based capital requirements. The Basel III minimum
More news about: BankFirst Capital Corporation
Apr 28, 2026, 07:00 ET Opera Reports First Quarter 2026 Results With Both Revenue and Adjusted EBITDA Exceeding High End of Guidance Ranges
defined as net income adjusted to exclude (i) profit (loss) from discontinued operations, (ii) gain (loss) on investments in unconsolidated entities, (iii) non-recurring expenses, (iv) impairment of non-financial assets, (v) amortization of acquired intangible assets, (vi) share-based compensation expenses,
More news about: Opera Limited
Apr 28, 2026, 07:00 ET Galaxy Announces First Quarter 2026 Financial Results
CoreWeave Leases (Phases I+II+III)
More news about: Galaxy Digital Inc.